Compare VET & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VET | VIR |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2004 | 2019 |
| Metric | VET | VIR |
|---|---|---|
| Price | $11.29 | $8.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $15.00 | ★ $19.43 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $14.07 | $270.22 |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.00 | $4.25 |
| 52 Week High | $14.82 | $11.66 |
| Indicator | VET | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 47.39 |
| Support Level | $11.14 | $8.43 |
| Resistance Level | $11.93 | $10.10 |
| Average True Range (ATR) | 0.38 | 0.41 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 66.86 | 41.14 |
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.